Israel
· Delayed Price · Currency is ILS · Price in ILA Purple Biotech Statistics
Total Valuation
Purple Biotech has a market cap or net worth of ILS 27.01 million. The enterprise value is -3.18 million.
| Market Cap | 27.01M |
| Enterprise Value | -3.18M |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 529.64 million shares outstanding. The number of shares has increased by 48.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 529.64M |
| Shares Change (YoY) | +48.17% |
| Shares Change (QoQ) | +18.40% |
| Owned by Insiders (%) | 0.50% |
| Owned by Institutions (%) | 3.06% |
| Float | 523.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.22 |
| P/TBV Ratio | 1.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.12 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.23, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.23 |
| Quick Ratio | 2.14 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -21.66% and return on invested capital (ROIC) is -19.93%.
| Return on Equity (ROE) | -21.66% |
| Return on Assets (ROA) | -16.60% |
| Return on Invested Capital (ROIC) | -19.93% |
| Return on Capital Employed (ROCE) | -32.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -2.93M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.67% in the last 52 weeks. The beta is -0.11, so Purple Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.11 |
| 52-Week Price Change | -79.67% |
| 50-Day Moving Average | 5.56 |
| 200-Day Moving Average | 8.85 |
| Relative Strength Index (RSI) | 42.31 |
| Average Volume (20 Days) | 459,263 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -225,823 |
| Operating Income | -39.35M |
| Pretax Income | -26.51M |
| Net Income | -26.37M |
| EBITDA | -39.22M |
| EBIT | -39.35M |
| Earnings Per Share (EPS) | -0.08 |
Balance Sheet
The company has 31.05 million in cash and 666,541 in debt, giving a net cash position of 30.38 million or 0.06 per share.
| Cash & Cash Equivalents | 31.05M |
| Total Debt | 666,541 |
| Net Cash | 30.38M |
| Net Cash Per Share | 0.06 |
| Equity (Book Value) | 119.87M |
| Book Value Per Share | 0.23 |
| Working Capital | 17.92M |
Cash Flow
| Operating Cash Flow | -52.33M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.17% |
| Shareholder Yield | -48.17% |
| Earnings Yield | -97.63% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on January 6, 2019. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jan 6, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |